Health
Vera reports positive Phase 3 trial results for kidney drug Trutakna
Trutakna stabilized kidney function in a Phase 3 study, according to STAT.
The short version
- Vera Therapeutics announced final two-year Phase 3 trial data showing Trutakna stabilized kidney function and lowered the risk of kidney-related death and complications.[STAT]
- The drug targets IgA nephropathy, a chronic autoimmune kidney disease caused by antibody accumulation.[STAT]
- Vera plans to leverage the full study data to submit an application for full FDA approval in the fourth quarter.[STAT]
Key facts
- Vera Therapeutics released final two-year Phase 3 results showing Trutakna stabilized kidney function and reduced kidney-related death and complications.[STAT]
- The FDA granted accelerated approval for Trutakna in July to treat IgA nephropathy.[STAT]
- Vera plans to apply for full FDA approval in the fourth quarter.[STAT]
What remains uncertain
- Full FDA approval remains pending the submission and regulatory review expected in the fourth quarter.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.